New Data on VimpatÃ‚® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society
ATLANTA, Nov. 30, 2011 /PRNewswire/ -- UCB, a leading biopharmaceutical company committed to the development of new epilepsy treatments and research, is proud to sponsor several key sets of Vimpat® (lacosamide) C-V data at the 65th Annual Meeting of the American Epilepsy Society (AES) in Baltimore, Md., December 2-6.
"At UCB, we are committed to working toward improving the lives of people living with epilepsy," said Dr. James Zackheim, Senior Medical Director, Central Nervous System Business Unit, UCB, Inc. "Therefore, we believe it is vitally important to invest in research to better understand the clinical profile of Vimpat®."
Vimpat® is indicated as an add-on therapy for the treatment of partial-onset seizures in adults with epilepsy. The most common adverse reactions reported in pivotal trials and occurring in 10 percent or more of Vimpat®-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia. Additional important safety information for Vimpat® is available at the end of the press release.
Following is a guide to UCB-sponsored posters for Vimpat® being exhibited during the AES annual meeting. To schedule an interview with an investigator, please contact Andrea Levin at 404.483.7329 or Andrea.Levin@ucb.com.
Vimpat® (lacosamide) C-V:
1. Evaluation of Long-Term Treatment with Lacosamide for Partial-Onset Seizures: A Pooled Analysis of Open-Label Extension Trials
Abstract 2.233; Poster Session 2: Sunday, December 4, 8am – 6pm
2. Effect of Long-Term Lacosamide on Patient-Reported Health-Related Quality of Life and Seizure Severity by Seizure Subtype
Abstract 2.244; Poster Session 2: Sunday, December 4, 8am – 6pm